Children’s Health Defense Petitions to Ban Infants’ Tylenol and Require Warnings
Children’s Health Defense (CHD) has filed a Citizen Petition with the U.S. Food and Drug Administration (FDA) urging the agency to ban over-the-counter Infants’ Tylenol and similar acetaminophen products. The petition also calls for the requirement of boxed warnings for children under six years old and for use during labor and delivery. Boxed warnings are the FDA’s most serious warning label, indicating significant hazards.
The petition highlights that Infants’ Tylenol does not provide a recommended dosage for children under two years old, instead advising parents to consult a doctor. This lack of clear guidance raises concerns about potential overdosing risks, especially since the product is available without a prescription. Current warnings primarily focus on liver toxicity, failing to inform parents about possible neurodevelopmental risks associated with acetaminophen use.
The petition is supported by what CHD describes as "31 lines of evidence," which include studies on acetaminophen metabolism, animal experiments, epidemiological research, and clinical observations. Notably, it references work by William Parker, Ph.D., of WPLab, Inc., who has raised alarms about acetaminophen use in infants and its association with autism spectrum disorder.
According to the petition, newborns and young infants possess immature metabolic pathways that limit their ability to detoxify acetaminophen, potentially leading to increased production of the toxic byproduct NAPQI. This vulnerability is said to decrease as children grow, reaching maturity around age six. A 2008 review in the Journal of Applied Toxicology indicates that acetaminophen’s primary toxic action is linked to the depletion of glutathione, resulting in the formation of NAPQI. Additionally, a comprehensive compilation of studies suggests that increased exposure to acetaminophen, particularly in the context of inflammation and oxidative stress, may pose neurotoxic risks to infants and young children due to their developmental metabolic limitations.
Functional medicine practitioners have suggested that rising autism rates cannot be solely explained by genetic or epigenetic factors, as noted in the Textbook of Natural Medicine, highlighting ongoing debates about whether the increase reflects improved diagnostic practices or a genuine rise in cases.
Brian Hooker, CHD’s chief scientific officer and a signatory of the petition, asserts that the evidence linking perinatal and postnatal acetaminophen use to neurological damage is "very clear," emphasizing that the drug has not been adequately tested for its potential neurological harm in infants and young children. Dr. Parker also commented on the petition, stating that it addresses key scientific oversights that have obscured the connection between acetaminophen and autism.
In response to these claims, Kenvue, the manufacturer of Tylenol, has submitted a 42-page rebuttal to the FDA, arguing that scientific evidence does not support a connection between acetaminophen and autism. Furthermore, recent legal developments have seen the 2nd U.S. Circuit Court of Appeals revive lawsuits against Kenvue, which allege that the company, along with retailers, was aware of the potential risks associated with acetaminophen.
Former President Donald Trump has advised pregnant women to avoid Tylenol and has called for a review of childhood vaccination schedules. The Department of Health and Human Services has indicated that the FDA plans to add warnings to Tylenol and other acetaminophen products regarding a possible link to autism. Reports have surfaced suggesting that FDA officials were aware of a potential link as early as 2016.
According to the CDC, one in 36 eight-year-old children were diagnosed with an autism spectrum disorder in 2020. Texas Attorney General Ken Paxton has also filed a lawsuit against Johnson & Johnson and Kenvue, accusing the companies of misleading marketing practices regarding Tylenol’s safety for pregnant women.
A Citizen Petition is a formal request for regulatory action from the FDA, which typically must respond within 150 to 180 days. CHD argues that waiting for randomized clinical trials would be impractical and ethically challenging, urging regulators to adopt the precautionary principle. The FDA will review the petition and determine whether regulatory action is warranted based on the scientific evidence presented.




